Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The ACR’s State-of-the-Art Clinical Symposium: Rheumatic, Malignant Disease Mimics Call for Diligence from Rheumatologists

Thomas R. Collins  |  Issue: July 2015  |  July 14, 2015

New-onset malignancies can mimic rheumatic disease, and viral infections may present with rheumatic symptoms.

New-onset malignancies can mimic rheumatic disease, and viral infections may present with rheumatic symptoms.
Image Credit: Dmytro Zinkevych/shutterstock

CHICAGO—David Daikh, MD, PhD, professor of medicine at the University of California San Francisco and chief of the Rheumatology Division at the San Francisco VA Medical Center, said the overlap between malignant disease and rheumatic disease means rheumatologists should stay aware that more may be going on than just a rheumatic disorder.

He made his remarks in a session on rheumatic disease “mimics” at the American College of Rheumatology’s 2015 State-of-the-Art Clinical Symposium in May in a session that also covered statin-induced myopathy and infections that might bring on arthritis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Malignancies

Dr. Daikh said rheumatologists can play an important role in catching malignancies early.

“Rheumatoid and musculoskeletal symptoms can be the initial manifestation of cancer, meaning we may be the first-line diagnosticians,” he said. New-onset malignancies can mimic rheumatic disease, and patients with rheumatic disease can be at increased risk of having early, subclinical cancers.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A malignancy can bring on rheumatic and musculoskeletal disease through primary or metastatic disease’s direct or indirect involvement of musculoskeletal structures, and through activation of autoimmune responses, he said.

Paraneoplastic syndromes can show rheumatic manifestations—skin and connective tissue symptoms, paraneoplastic arthritis or vasculitis—and malignancy that’s linked with using antirheumatic therapy.

Sclerodermatous skin changes, for example, have been associated with breast, ovarian, pulmonary and gastrointestinal cancers, and Raynaud’s phenomenon can also be a main manifestation of a malignancy.

“Carcinoma polyarthritis”—an inflammatory neoplastic arthropathy similar to late-onset RA—has been linked to solid tumors.

It’s a two-way street, Dr. Daikh said: RA, Sjögren’s syndrome and inflammatory myopathies can bring an increased risk of malignancy.

An association has been found between dermatomyositis and malignancy, particularly in those older than 45, with most cancers presenting within a year before or after the myositis diagnosis.

If an older patient has an unexplained or atypical myositis and responds poorly to therapy, an aggressive work-up of signs and symptoms is in order, Dr. Daikh said.

In one of his cases, a 59-year-old man with typical signs of dermatomyositis was put on prednisone. After two weeks, he reported some improvements, but then also reported abdominal pain and nausea. He immediately got an abdominal CT, and multiple liver masses were found.

“The take-home message that I’ve had from my patients,” Dr. Daikh said, “is that my threshold has to be lower for going beyond age-appropriate screening.”

Statin-Induced Myopathy

Dr. Mammen

Dr. Mammen

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsMeeting Reports Tagged with:AC&Rclinical symposiumDiagnosisDiseasemalignantmimicspatient carerheumaticrheumatologistTreatment

Related Articles

    Meet the HEP C Challenge

    December 1, 2008

    Keep a hepatitis C virus infection from hindering RA treatment

    Drug Updates

    January 1, 2009

    Information on safety, labeling changes, and pharmaceutical research

    Fellows’ Forum Case Report: Necrotizing Autoimmune Myopathy

    December 18, 2017

    Necrotizing autoimmune myopathy (NAM) is a relatively recently discovered subgroup of inflammatory myopathies. NAM is characterized by predominant muscle fiber necrosis and regeneration with little or no inflammation.1 One subgroup of NAM is 3-hydroxy-3-methylglutaryl-CoA reductase antibody (HMGCR Ab)-related immune-mediated necrotizing myopathy (IMNM), which occurs (rarely) after statin exposure, with a rough incidence of two per…

    New Tools for Myositis Diagnosis, Classification & Management

    April 15, 2019

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences